EQT AB is nearing a deal to acquire Qiagen NV for around €9.6 billion ($10.8 billion) bringing an end to years of takeover speculation involving the European molecular testing company, according to people familiar with the matter.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.